Overview

Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
- Introduction: Estrogen hormonal therapy associated or not with progestagen is the standard therapy for the treatment of hot flushes. However some women are not candidates for hormone replacement therapy for medical reasons or for choice. - Main goal: Reducing the number of hot flushes per week - Materials and Methods: A double-blind sulpiride versus placebo that includes selected randomized patients which show symptoms of menopause. The study will be conducted at HC Porto Alegre (Brazil) for 8 weeks of intervention. The expected result is a significant reduction in the number of hot flushes/day evaluated by daily questionnaires
Phase:
Phase 3
Details
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Treatments:
Sulpiride